Tg Therapeutics (TGTX) Gross Profit (2021 - 2026)

Tg Therapeutics' Gross Profit history runs 6 years deep, the most recent figure standing at $171.4 million for Q1 2026.

• In Q1 2026, Gross Profit rose 62.76% year-over-year to $171.4 million; the TTM figure through Mar 2026 stood at $581.7 million (up 72.19% YoY), while the FY2025 annual figure was $515.6 million, up 77.47% from the prior year.
• Gross Profit was $171.4 million for Q1 2026 at Tg Therapeutics, up from $154.4 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $171.4 million in Q1 2026 to a low of $77000.0 in Q4 2022.
• Historically, Gross Profit has averaged $79.8 million across 5 years, with a median of $74.5 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Gross Profit soared 176319.57% in 2023, then tumbled 54.08% in 2024.
• A 5-year view of Gross Profit shows it stood at $77000.0 in 2022, then jumped by 46805.19% to $36.1 million in 2023, then soared by 156.9% to $92.8 million in 2024, then surged by 66.44% to $154.4 million in 2025, then advanced by 10.99% to $171.4 million in 2026.
• The last three Gross Profit figures came in at $171.4 million (Q1 2026), $154.4 million (Q4 2025), and $133.6 million (Q3 2025), per Business Quant data.